Tumor mutational burden predicts neoantigen profiles and immunotherapy response in microsatellite stable tumors across different cancer types.

ABSTRACT:

Introduction

Immunotherapy has shown positive response in many patients with microsatellite instable (MSI-H) tumors, but its effectiveness in microsatellite stable (MSS) tumors remains limited. We hypothesize that tumor mutational burden (TMB) can help identify a biologically distinct subset of MSS tumors that can benefit from immunotherapy.

Methods

We analyzed the molecular characteristics, including mutational landscape, mutational signatures, immune cell profiles and neoantigen load of MSS tumors with high TMB using data from colorectal cancer datasets (TCGA-COAD and TCGA-READ). After that, we extended these findings across other cancer types with MSI classification, further supporting the potential of using TMB as a biomarker for predicting immunotherapy response in MSS

SUBMITTER: Kondrateva O 

PROVIDER: S-EPMC12824007 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature